<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2019.10393</article-id>
<article-id pub-id-type="publisher-id">mmr-20-02-1925</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SFRP2 modulates non-small cell lung cancer A549 cell apoptosis and metastasis by regulating mitochondrial fission via Wnt pathways</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Peng</given-names></name>
<xref rid="af1-mmr-20-02-1925" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Shu</given-names></name>
<xref rid="af2-mmr-20-02-1925" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Hu</surname><given-names>Yi</given-names></name>
<xref rid="af1-mmr-20-02-1925" ref-type="aff">1</xref>
<xref rid="c1-mmr-20-02-1925" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-mmr-20-02-1925"><label>1</label>Department of Oncology, The First Medical Center, Chinese People&#x0027;s Liberation Army General Hospital, Beijing 100853, P.R. China</aff>
<aff id="af2-mmr-20-02-1925"><label>2</label>Department of Oncology, The Second Medical Center, Chinese People&#x0027;s Liberation Army General Hospital, Beijing 100853, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-20-02-1925"><italic>Correspondence to</italic>: Professor Yi Hu, Department of Oncology, The First Medical Center, Chinese People&#x0027;s Liberation Army General Hospital, 28 Fu Xing Road, Beijing 100853, P.R. China, E-mail: <email>huyi0401@aliyun.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>08</month><year>2019</year></pub-date>
<pub-date pub-type="epub"><day>18</day><month>06</month><year>2019</year></pub-date>
<volume>20</volume>
<issue>2</issue>
<fpage>1925</fpage>
<lpage>1932</lpage>
<history>
<date date-type="received"><day>02</day><month>01</month><year>2019</year></date>
<date date-type="accepted"><day>20</day><month>05</month><year>2019</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2019, Spandidos Publications</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<p>The secreted frizzled-related protein 2 (SFRP2) has been reported to inhibit non-small cell lung cancer (NSCLC) cell survival and metastasis; however, the underlying mechanisms are yet to be fully determined. The present study focused on mitochondrial fission and the Wnt signaling pathway. The results demonstrated that SFRP2 was downregulated in the NSCLC cell line A549 compared with in a normal pulmonary epithelial cell line using western blotting, reverse transcription-quantitative PCR and immunofluorescence. Subsequently, it was demonstrated that SFRP2 overexpression promoted the apoptosis, and inhibited the proliferation and metastasis of A549 cells using MTT assays, TUNEL staining and 5-ethynyl-2&#x2032;-deoxyuridine labeling. At the molecular level, the overexpression of SFRP2 in A549 cells led to the activation of mitochondrial fission by inhibiting the Wnt signal pathway. Excessive mitochondrial fission induced low ATP generation, impaired mitochondrial respiratory function, induced mitochondrial potential depolarization, and increased mitochondrial permeability transition pore opening, and imbalances in pro- and antiapoptotic protein expression. Furthermore, mitochondrial fission was involved in the inhibition of A549 cell proliferation and metastasis. Thus, SFRP2 may inhibit the survival and metastasis of NSCLC cells via the Wnt/mitochondrial fission pathway.</p>
</abstract>
<kwd-group>
<kwd>SFRP2</kwd>
<kwd>apoptosis</kwd>
<kwd>NSCLC</kwd>
<kwd>Wnt</kwd>
<kwd>mitochondrial fission</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Non-small cell lung cancer (NSCLC) is a lung malignancy that seriously threatens human health, and its poor prognosis largely results from cancer cell survival and metastasis (<xref rid="b1-mmr-20-02-1925" ref-type="bibr">1</xref>&#x2013;<xref rid="b3-mmr-20-02-1925" ref-type="bibr">3</xref>). The methods of radiotherapy and chemotherapy used to treat NSCLC have improved; however, the 5-year survival of patients with NSCLC remains poor (<xref rid="b4-mmr-20-02-1925" ref-type="bibr">4</xref>&#x2013;<xref rid="b7-mmr-20-02-1925" ref-type="bibr">7</xref>). Therefore, strategies that suppress cancer cell survival and metastasis are required for the treatment of NSCLC.</p>
<p>Secreted frizzled-related protein 2 (SFRP2) belongs to the SFRP family and functions as a negative regulator of canonical Wnt signaling (<xref rid="b8-mmr-20-02-1925" ref-type="bibr">8</xref>). Previous studies have demonstrated that SFRP2 expression was downregulated in NSCLC specimens, and is an indicator of poor prognosis (<xref rid="b9-mmr-20-02-1925" ref-type="bibr">9</xref>,<xref rid="b10-mmr-20-02-1925" ref-type="bibr">10</xref>). Additionally, SFRP2 overexpression was reported to inhibit the survival and migration of A549 NSCLC cells (<xref rid="b11-mmr-20-02-1925" ref-type="bibr">11</xref>). These results suggested that SFRP2 acts as a tumor suppressor by inhibiting cellular survival and migration; however, the molecular mechanisms underlying the functions of SFRP2 in NSCLC remain unclear.</p>
<p>Mitochondria have been reported to serve important roles in numerous types of cancer cells (<xref rid="b12-mmr-20-02-1925" ref-type="bibr">12</xref>,<xref rid="b13-mmr-20-02-1925" ref-type="bibr">13</xref>). Impaired mitochondrial function inhibited cancer cell migration, invasion and survival, and increased cancer cell apoptosis (<xref rid="b14-mmr-20-02-1925" ref-type="bibr">14</xref>). Dynamin-related protein 1 (Drp1)-associated mitochondrial fission serves an important role in the regulation of mitochondrial function (<xref rid="b15-mmr-20-02-1925" ref-type="bibr">15</xref>&#x2013;<xref rid="b19-mmr-20-02-1925" ref-type="bibr">19</xref>). Additionally, a recent study determined that mitochondrial fission was involved in the regulation of A549 NSCLC cell survival and migration (<xref rid="b20-mmr-20-02-1925" ref-type="bibr">20</xref>). Therefore, it was hypothesized that SFRP2 may reduce NSCLC A549 cell survival and migration by activating mitochondrial fission.</p>
<p>SFRP2 is a negative regulator of the Wnt signaling pathway (<xref rid="b8-mmr-20-02-1925" ref-type="bibr">8</xref>) and functions via the Wnt signaling pathway in diverse developmental processes, including cellular apoptosis, migration, adhesion and proliferation (<xref rid="b21-mmr-20-02-1925" ref-type="bibr">21</xref>). Furthermore, the Wnt signaling pathway has been reported to participate in the regulation of mitochondrial function and mitochondria-dependent cell apoptosis (<xref rid="b22-mmr-20-02-1925" ref-type="bibr">22</xref>&#x2013;<xref rid="b25-mmr-20-02-1925" ref-type="bibr">25</xref>). Thus, it was proposed that SFRP2 may activate mitochondrial fission via the Wnt signaling pathway. The aim of the present study was to investigate the role of mitochondrial fission in SFRP2-mediated suppression of cancer phenotypes in A549 NSCLC cells, with a focus on the Wnt signaling pathway.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture and treatments</title>
<p>The normal pulmonary epithelial cell line BEAS-2B and the NSCLC cell line A549 were purchased from the American Type Culture Collection and cultured in low glucose-Dulbecco&#x0027;s Modified Eagle&#x0027;s medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10&#x0025; fetal bovine serum (Gibco, USA) and 1&#x0025; streptomycin and penicillin at 37&#x00B0;C in humidified air with 5&#x0025; CO<sub>2</sub>. To inhibit the Wnt pathway, inhibitor of Wnt response-1 (IWR-1; 8 &#x00B5;mol/l; cat. no. S7086; Selleck Chemicals) was added to the medium for 4 h, as previously described (<xref rid="b26-mmr-20-02-1925" ref-type="bibr">26</xref>). To inhibit mitochondrial fission, cells were exposed to mitochondrial division inhibitor 1 (Mdivi1; 10 mM; Sigma-Aldrich; Merck KGaA) for 12 h at 37&#x00B0;C after transduction of A549 cells with an SFRP2 overexpression vector (ad-SFRP2).</p>
</sec>
<sec>
<title>SFRP2 overexpression</title>
<p>The SFRP2/pLenti6/UbC/V5-DEST vector (ad-SFRP2) and control adenovirus plasmid (ad-ctrl) were purchased from Vigene Biosciences, Inc. ad-sFRP2 (20 nM) and ad-ctrl (20 nM) were used to infect A549 cells with Lipofectamine&#x2122; 2000 (Thermo Fisher Scientific, Inc.) for 48 h, and the transduction efficiency was determined by western blotting.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative PCR (RT-qPCR)</title>
<p>Total RNA was extracted from cells using a Trizol kit (Beyotime Institute of Biotechnology). Reverse transcription was performed using a TaqMan MicroRNA Reverse Transcription kit (Takara Bio, Inc.) at 37&#x00B0;C for 30 min, according to the manufacturer&#x0027;s instructions. qPCR was performed using the SYBR Green RT-PCR kit (Takara Bio, Inc.). The thermocycling conditions were as follows: 95&#x00B0;C for 5 min, followed by 40 cycles of 95&#x00B0;C for 40 sec, 60&#x00B0;C for 30 sec and 72&#x00B0;C for 30 sec. The following primers were used for qPCR: SFRP2, forward 5&#x2032;-AGGACAACGACCTTTGCATC-3&#x2032;, reverse 5&#x2032;-TCATTTTTATTTTTGCAGGCTTC-3&#x2032;; GAPDH, forward 5&#x2032;-GTCAACGGATTTGGTCGTATTG-3&#x2032;, reverse 5&#x2032;-CATGGGTGGAATCATATTGGAA-3&#x2032;. GAPDH was used as an internal control. Fold-changes were calculated using the 2<sup>&#x2212;&#x0394;&#x0394;Cq</sup> method (<xref rid="b27-mmr-20-02-1925" ref-type="bibr">27</xref>).</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Samples were homogenized and sonicated in precooled RIPA lysis buffer (Beyotime Institute of Biotechnology). The protein concentration was determined using a BCA Protein Quantification kit. Proteins (50 &#x00B5;g) were separated using 10&#x0025; SDS-PAGE and transferred onto PVDF membranes. The membrane was first blocked with 5&#x0025; non-fat dry milk for 1 h at room temperature, and then incubated with specific primary antibodies overnight at 4&#x00B0;C. Then, the membranes were incubated with secondary antibodies for 1 h at room temperature. The antibodies used for immunoblotting were as follows: SFRP2 (1:1,000; cat. no. ab92667; Abcam); c-myc (1:1,000; cat. no. 9402; Cell Signaling Technology, Inc.); Bax (1:1,000; cat. no. 32503; Cell Signaling Technology, Inc.); &#x03B2;-catenin (1:1,000; cat. no. ab32572; Abcam); caspase-3 (1:1,000; cat. no. ab13847; Abcam), dynamin-1-like protein (1:1,000; cat. no. ab56788; Abcam), GAPDH (1:1,000; cat. no. ab8245; Abcam), cellular inhibitor of apoptosis protein 1 (c-IAP; 1:1,000; cat. no. 3130; Cell Signaling Technology, Inc.), horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin (Ig)G (1:1,000; cat. no. 7076; Cell Signaling Technology, Inc.) and HRP-conjugated anti-rabbit IgG (1:1,000; cat. no. 7074; Cell Signaling Technology, Inc.). Bands were detected using an enhanced chemiluminescence substrate kit (Thermo Fisher Scientific, Inc.). Blots were scanned and quantified using ImageJ version 1.47 software (National Institutes of Health).</p>
</sec>
<sec>
<title>ATP production, mitochondrial membrane potential (&#x0394;&#x03A8;m) and mitochondrial permeability transition pore (mPTP) opening</title>
<p>The cellular ATP levels were measured using a firefly luciferase-based ATP assay kit (S0026; Beyotime Institute of Biotechnology) using a luminometer (Genmed Scientifics Inc.), as previously described (<xref rid="b28-mmr-20-02-1925" ref-type="bibr">28</xref>).</p>
<p>A JC-1 kit (Beyotime Institute of Biotechnology) was used to measure the change in the mitochondrial membrane potential (&#x0394;&#x03A8;m). Cells (1&#x00D7;10<sup>5</sup> cells/well) were seeded into a 6-well plate. After treatment, cells were incubated with 2 &#x00B5;M JC-1 at 37&#x00B0;C for 10 min. Images of five random fields were captured using a fluorescent microscope (OLYMPUS DX51; Olympus Corporation) and were analyzed using Image-Pro Plus 6.0 (Media Cybernetics) to obtain the mean densities of the region of interest, which was normalized to that of the control group. The opening of the mPTP was observed as the rapid dissipation of tetramethylrhodamine ethyl ester fluorescence as previously described (<xref rid="b29-mmr-20-02-1925" ref-type="bibr">29</xref>).</p>
</sec>
<sec>
<title>Cell proliferation, migration and invasion</title>
<p>A 5-ethynyl-2&#x2032;-deoxyuridine (EdU) incorporation assay was performed using an EdU kit (cat. no. A10044; Thermo Fisher Scientific, Inc.). Briefly, EdU (2 nM/well) was diluted in complete culture medium, and the cells (1&#x00D7;10<sup>6</sup>) were incubated with the dilution for 2 h at 37&#x00B0;C. Subsequently, the cells were fixed with 4&#x0025; paraformaldehyde for 15 min at 37&#x00B0;C and then incubated with Apollo Staining reaction liquid for 30 min. DAPI (5 mg/ml) was used to stain the nuclei for 3 min at room temperature.</p>
<p>Following treatment, A549 cell migration and invasion was analyzed using a Transwell chamber assay (24 wells) as previously described (<xref rid="b30-mmr-20-02-1925" ref-type="bibr">30</xref>). Briefly, cells were suspended in serum-free medium and seeded into upper chambers that were either uncoated (for the migration assay) or coated (for the invasion assay) with BD Matrigel&#x2122; Basement Membrane Matrix.</p>
</sec>
<sec>
<title>MTT assay and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay</title>
<p>Cells were seeded at 8&#x00D7;10<sup>3</sup> cells/well into 96-well plates and incubated overnight at 37&#x00B0;C. Following treatment, MTT (5 mg/ml) was added to each well, and cells were incubated for a further 4 h at 37&#x00B0;C, following which the supernatants were removed. The cells were solubilized in 200 &#x00B5;l dimethyl sulfoxide and the absorbance was detected using a microplate reader at 490 nm.</p>
<p>A TUNEL assay was used to detect cellular death. Following treatment, cells were fixed using 4&#x0025; paraformaldehyde for 10 min at room temperature. Cells were then incubated with fluorescein-dUTP (Invitrogen; Thermo Fisher Scientific, Inc.), to stain apoptotic cell nuclei, and with DAPI (5 mg/ml), to stain all cell nuclei, at room temperature for 3 min. Images of at least five random fields were captured under a confocal microscope (Olympus Corporation).</p>
</sec>
<sec>
<title>Immunofluorescence staining</title>
<p>Cells were fixed in 4&#x0025; paraformaldehyde at room temperature for 10 min. Cells were then labeled with primary antibodies at 4&#x00B0;C overnight. PBS was used to wash the samples three times and the samples were stained with a fluorescent secondary antibody at 37&#x00B0;C for 30 min. The following primary antibodies were used for immunofluorescence: Mitochondrial import receptor subunit TOM20 homolog (1:500; cat. no. ab56783; Abcam), SFRP2 (1:500; cat. no. ab92667; Abcam). The following secondary antibodies were used: Anti-rabbit IgG (1:500, cat. no. 4413; Alexa Fluor<sup>&#x00AE;</sup> 555; Cell Signaling Technology, Inc.) anti-mouse IgG (1:500; 4408; Alexa Fluor<sup>&#x00AE;</sup> 488; Cell Signaling Technology, Inc.). Images in which cells were not clustered were obtained using a confocal microscope; the image were analyzed using ImageJ 1.47 version software. DAPI (5 mg/ml; Sigma-Aldrich; Merck KGaA) was used to stain the nuclei at room temperature for 10 min.</p>
</sec>
<sec>
<title>Electron transport chain complexes (ETCx) activity detection</title>
<p>Complex I, II, and V activity was determined according to a previous study (<xref rid="b31-mmr-20-02-1925" ref-type="bibr">31</xref>). Mitochondrial respiratory function was measured polarographically at 30&#x00B0;C using a Biological Oxygen Monitor System (Hansatech Instruments, Ltd.) and a Clarktype oxygen electrode (Hansatech Instruments, Ltd.). Mitochondrial respiration was induced by adding glutamate and malate to a final concentration of 5 and 2.5 mmol/liter, respectively.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Experiments were repeated three times, and data were presented as the mean &#x00B1; standard error of the mean. Statistical analyses were performed using one-way analysis of variance followed by a Bonferroni post hoc test. P&#x003C;0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc.).</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Overexpression of SFRP2 is associated with NSCLC A549 cell apoptosis</title>
<p>A previous study reported that SFRP2 was downregulated in NSCLC specimens (<xref rid="b11-mmr-20-02-1925" ref-type="bibr">11</xref>). To investigate the role of SRFP2 in the phenotypes of A549 cells, western blotting and RT-qPCR analyses were conducted to measure the expression of SFRP2 in the NSCLC cell line A549 and normal pulmonary epithelial cell line BEAS-2B. As presented in <xref rid="f1-mmr-20-02-1925" ref-type="fig">Fig. 1A-C</xref>, the protein and mRNA expression levels of SFRP2 were significantly decreased in A549 cells compared with BEAS-2B cells. Similar results were observed using an immunofluorescence assay (<xref rid="f1-mmr-20-02-1925" ref-type="fig">Fig. 1D and E</xref>). Subsequently, the expression of SFRP2 was upregulated in A549 cells via adenoviral vector infection. The transfection efficiency was demonstrated via western blot analysis (<xref rid="f1-mmr-20-02-1925" ref-type="fig">Fig. 1F and G</xref>). The viability and apoptosis of A549 cells following SFRP2 overexpression were measured using MTT and TUNEL assays, respectively. Overexpression of SFPR2 significantly reduced the viability (<xref rid="f1-mmr-20-02-1925" ref-type="fig">Fig. 1H</xref>), and significantly promoted the apoptosis of A549 cells (<xref rid="f1-mmr-20-02-1925" ref-type="fig">Fig. 1I and J</xref>). The results demonstrated that SFRP2 may function as a tumor suppressor in A549 cells by promoting cancer cell apoptosis.</p>
</sec>
<sec>
<title>SFRP2 activates A549 cell apoptosis via mitochondrial dysfunction</title>
<p>Previous studies reported that mitochondrial dysfunction was involved in cancer cell apoptosis (<xref rid="b12-mmr-20-02-1925" ref-type="bibr">12</xref>,<xref rid="b32-mmr-20-02-1925" ref-type="bibr">32</xref>). To investigate the underlying mechanisms of SFRP2 in relation to A549 cell apoptosis, mitochondrial function was measured in A549 cells in the presence or absence of SFRP2 overexpression. As presented in <xref rid="f2-mmr-20-02-1925" ref-type="fig">Fig. 2A</xref>, upregulation of SFRP2 decreased ATP generation compared with the control. Maintenance of the &#x0394;&#x03A8;m is required for ATP generation (<xref rid="b29-mmr-20-02-1925" ref-type="bibr">29</xref>,<xref rid="b33-mmr-20-02-1925" ref-type="bibr">33</xref>). Compared with the control, SFRP2 overexpression depolarized the &#x0394;&#x03A8;m, as indicated by decreased red fluorescence and increased green fluorescence (<xref rid="f2-mmr-20-02-1925" ref-type="fig">Fig. 2B and C</xref>). In addition, SFRP2 overexpression significantly promoted mPTP opening (<xref rid="f2-mmr-20-02-1925" ref-type="fig">Fig. 2D</xref>), and inhibited the activity of the mitochondrial respiratory complex (<xref rid="f2-mmr-20-02-1925" ref-type="fig">Fig. 2E-G</xref>). Via western blotting (<xref rid="f2-mmr-20-02-1925" ref-type="fig">Fig. 2H-K</xref>), it was revealed that SFRP2 overexpression significantly increased the expression of proapoptotic proteins (caspase3 and Bax) and decreased the expression of c-IAP compared with the control. Collectively, these findings suggested that overexpression of SFRP2 may activate mitochondrial-dependent apoptotic pathways in A549 cells.</p>
</sec>
<sec>
<title>SFRP2 contributes to mitochondrial damage via mitochondrial fission in A549 cells</title>
<p>Previous studies reported that mitochondrial fission was involved in mitochondrial dysfunction and preceded apoptosis in various types of cancer cell (<xref rid="b15-mmr-20-02-1925" ref-type="bibr">15</xref>,<xref rid="b34-mmr-20-02-1925" ref-type="bibr">34</xref>). Thus, whether SFRP2 induced A549 cell apoptosis via mitochondrial fission was investigated. As presented in <xref rid="f3-mmr-20-02-1925" ref-type="fig">Fig. 3A</xref>, numerous mitochondrial fragments were observed in ad-SFRP2 cells, but not in control or ad-ctrl cells. Mdivi1, a mitochondrial fission inhibitor, was used in ad-SFRP2 cells to inhibit mitochondrial fission. Quantification of mitochondrial length revealed similar results (<xref rid="f3-mmr-20-02-1925" ref-type="fig">Fig. 3B</xref>). Additionally, inhibiting mitochondrial fission significantly increased ATP generation (<xref rid="f3-mmr-20-02-1925" ref-type="fig">Fig. 3C</xref>) and inhibited mPTP opening in ad-SFRP2 cells (<xref rid="f3-mmr-20-02-1925" ref-type="fig">Fig. 3D</xref>), and reduced the number of TUNEL-positive cells (<xref rid="f3-mmr-20-02-1925" ref-type="fig">Fig. 3E</xref>), compared with the control. Thus, these findings indicated that SFPR2 overexpression induced A549 cell mitochondrial dysfunction and apoptosis by activating mitochondrial fission.</p>
</sec>
<sec>
<title>Excessive mitochondrial fission inhibits A549 cell proliferation and metastasis</title>
<p>The effects of SFRP2 were measured on A549 cell proliferation and metastasis, key determinants of malignant progression and metastasis. Using an EdU assay, it was demonstrated that the number of EdU-positive cells was significantly reduced following SFRP2 overexpression compared with the control (<xref rid="f4-mmr-20-02-1925" ref-type="fig">Fig. 4A and B</xref>); however, this was reversed by inhibiting mitochondrial fission via the application of Mdivi1. Furthermore, Transwell assays revealed that the migratory and invasive abilities of A549 cells were significantly decreased following SFRP2 overexpression compared with the control, but that this effect was attenuated following mitochondrial fission inhibition (<xref rid="f4-mmr-20-02-1925" ref-type="fig">Fig. 4C-E</xref>). These findings indicated that SFRP2 inhibited A549 cell proliferation and metastasis by activating mitochondrial fission.</p>
</sec>
<sec>
<title>SFRP2 activates mitochondrial fission via inhibiting Wnt signaling</title>
<p>As SFRP2 is an antagonist of the Wnt signaling pathway, whether SFRP2 activated mitochondrial fission via the Wnt signaling was investigated. IWR-1, an inhibitor of Wnt signaling, was applied to A549 cells. Compared with the control group, overexpression of SFRP2 and treatment with IWR-1 significantly reduced the protein levels of &#x03B2;-catenin and c-myc (<xref rid="f5-mmr-20-02-1925" ref-type="fig">Fig. 5A-C</xref>). To investigate the role of Wnt signaling in mitochondrial fission, the expression of Drp1 was evaluated via western blotting. Overexpression of SFRP2 and IWR-1 significantly upregulated the expression of Drp1 (<xref rid="f5-mmr-20-02-1925" ref-type="fig">Fig. 5A and D</xref>). Collectively, these findings indicated that SFRP2 regulated mitochondrial fission by inhibiting the Wnt signaling pathway.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The role of SFRP2 in NSCLC has been previously studied, suggesting that the loss of SFPR2 contributed to the development and progression of NSCLC (<xref rid="b11-mmr-20-02-1925" ref-type="bibr">11</xref>,<xref rid="b35-mmr-20-02-1925" ref-type="bibr">35</xref>); however, the underlying mechanisms remain unclear. In the present study, it was observed that SFRP2 overexpression decreased the survival, proliferation and metastasis of A549 NSCLC cells via the Wnt/mitochondrial fission pathway.</p>
<p>Functional tests into the involvement of mitochondrial function in cancer has revealed its importance over the past decade (<xref rid="b36-mmr-20-02-1925" ref-type="bibr">36</xref>,<xref rid="b37-mmr-20-02-1925" ref-type="bibr">37</xref>). Depleting mitochondria from tumor cells via the inactivation of mitochondrial transfection factor A impaired K-ras lung tumor growth in autochthonous models (<xref rid="b38-mmr-20-02-1925" ref-type="bibr">38</xref>). Reactive oxygen species generated from cross-talk between mitochondrial dysfunction and ER stress abrogated breast cancer progression via the JNK pathway (<xref rid="b39-mmr-20-02-1925" ref-type="bibr">39</xref>). Additionally, NSCLC cells are more sensitive to alterations in mitochondrial function compared with normal cells (<xref rid="b12-mmr-20-02-1925" ref-type="bibr">12</xref>). Acute autophagy ablation in mice with preexisting NSCLC blocked tumor growth, promoted tumor cell death, and led to the development of more benign disease (<xref rid="b40-mmr-20-02-1925" ref-type="bibr">40</xref>). These findings suggested that targeting mitochondria may provide novel therapeutic opportunities. Consistent with these findings, the present study demonstrated an important role for mitochondrial damage in the inhibition of cancer cell migration, and the induction of apoptosis and proliferation arrest.</p>
<p>SFRP2 functions as a negative regulator of canonical Wnt signaling (<xref rid="b8-mmr-20-02-1925" ref-type="bibr">8</xref>,<xref rid="b41-mmr-20-02-1925" ref-type="bibr">41</xref>,<xref rid="b42-mmr-20-02-1925" ref-type="bibr">42</xref>). To investigate the mechanisms underlying the effects of SFRP2 on mitochondria, Wnt signaling was evaluated. Previous studies reported an association between Wnt signaling and mitochondrial function (<xref rid="b43-mmr-20-02-1925" ref-type="bibr">43</xref>,<xref rid="b44-mmr-20-02-1925" ref-type="bibr">44</xref>). In tendon stem cells, activating Wnt signaling significantly reduced cell apoptosis via the mitochondrial/caspase-3 pathway (<xref rid="b45-mmr-20-02-1925" ref-type="bibr">45</xref>). In cerebral ischemia-reperfusion injury, Nur77 induced augmented mitochondrial fragmentation and N2a neuroblastoma cell apoptosis via an abnormal Wnt/&#x03B2;-catenin/inverted formin 2 pathway (<xref rid="b46-mmr-20-02-1925" ref-type="bibr">46</xref>). Inhibition of Wnt signal pathway by &#x03B2;-asarone inhibited metastasis and promoted mitochondria-associated apoptosis in lung cancer cells (<xref rid="b44-mmr-20-02-1925" ref-type="bibr">44</xref>). In accordance with these findings, the present study demonstrated that inhibition of Wnt signaling promoted the apoptosis of A549 NSCLC cells by activating Drp1-mediated mitochondrial fission.</p>
<p>In conclusion, the present study revealed that SFRP2 inhibited A549 NSCLC cell survival and metastasis, by regulating the Wnt/mitochondrial fission axis. The present study possessed certain limitations. For example, the activation of mitochondrial fission is strictly regulated by Drp1 and its receptors. Which receptor is involved in SFRP2-regulated mitochondrial fission remains unclear and requires further investigation. Additionally, the role of mitochondrial fission in NSCLC growth should be further explored in animal models.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>No funding was received.</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The data and materials used and/or analyzed during the present study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>PL and SZ were involved in conception and design, performance of experiments and the writing of the manuscript. PL, SZ and YH were involved in data analysis and interpretation.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-mmr-20-02-1925"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>FX</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>DD</given-names></name><name><surname>Chen</surname><given-names>HB</given-names></name></person-group><article-title>Hypoxic markers in non-small cell lung cancer (NSCLC)-A review</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>20</volume><fpage>849</fpage><lpage>852</lpage><year>2016</year><pub-id pub-id-type="pmid">27010140</pub-id></element-citation></ref>
<ref id="b2-mmr-20-02-1925"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>WY</given-names></name><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>CK</given-names></name><name><surname>Chen</surname><given-names>JQ</given-names></name><name><surname>Hua</surname><given-names>KT</given-names></name><name><surname>Cheng</surname><given-names>CW</given-names></name><name><surname>Hsiao</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>CL</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Chien</surname><given-names>MH</given-names></name></person-group><article-title>Leukocyte cell-derived chemotaxin 2 retards non-small cell lung cancer progression through antagonizing MET and EGFR activities</article-title><source>Cell Physiol Biochem</source><volume>51</volume><fpage>337</fpage><lpage>355</lpage><year>2018</year><pub-id pub-id-type="doi">10.1159/000495233</pub-id><pub-id pub-id-type="pmid">30453282</pub-id></element-citation></ref>
<ref id="b3-mmr-20-02-1925"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Lv</surname><given-names>HY</given-names></name><name><surname>Zhou</surname><given-names>DM</given-names></name><name><surname>Zhang</surname><given-names>EN</given-names></name></person-group><article-title>miR-204 suppresses non-small-cell lung carcinoma (NSCLC) invasion and migration by targeting JAK2</article-title><source>Genet Mol Res</source><volume>15</volume><year>2016</year><comment>doi: 10.4238/gmr.15026415</comment><pub-id pub-id-type="pmcid">6097843</pub-id></element-citation></ref>
<ref id="b4-mmr-20-02-1925"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brueckl</surname><given-names>WM</given-names></name><name><surname>Achenbach</surname><given-names>HJ</given-names></name><name><surname>Ficker</surname><given-names>JH</given-names></name><name><surname>Schuette</surname><given-names>W</given-names></name></person-group><article-title>Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice-results from the ElderTac study</article-title><source>BMC Cancer</source><volume>18</volume><fpage>333</fpage><year>2018</year><pub-id pub-id-type="doi">10.1186/s12885-018-4208-x</pub-id><pub-id pub-id-type="pmid">29587656</pub-id><pub-id pub-id-type="pmcid">5870245</pub-id></element-citation></ref>
<ref id="b5-mmr-20-02-1925"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tata</surname><given-names>PR</given-names></name><name><surname>Chow</surname><given-names>RD</given-names></name><name><surname>Saladi</surname><given-names>SV</given-names></name><name><surname>Tata</surname><given-names>A</given-names></name><name><surname>Konkimalla</surname><given-names>A</given-names></name><name><surname>Bara</surname><given-names>A</given-names></name><name><surname>Montoro</surname><given-names>D</given-names></name><name><surname>Hariri</surname><given-names>LP</given-names></name><name><surname>Shih</surname><given-names>AR</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Developmental history provides a roadmap for the emergence of tumor plasticity</article-title><source>Dev Cell</source><volume>44</volume><fpage>679</fpage><lpage>693.e5</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.devcel.2018.02.024</pub-id><pub-id pub-id-type="pmid">29587142</pub-id><pub-id pub-id-type="pmcid">5875457</pub-id></element-citation></ref>
<ref id="b6-mmr-20-02-1925"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>M</given-names></name><name><surname>McMurry</surname><given-names>T</given-names></name><name><surname>Meyers</surname><given-names>BF</given-names></name><name><surname>Puri</surname><given-names>V</given-names></name><name><surname>Kozower</surname><given-names>BD</given-names></name></person-group><article-title>Long-term results for clinical stage ia lung cancer: Comparing lobectomy and sublobar resection</article-title><source>Ann Thorac Surg</source><volume>106</volume><fpage>375</fpage><lpage>381</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.02.049</pub-id><pub-id pub-id-type="pmid">29580779</pub-id></element-citation></ref>
<ref id="b7-mmr-20-02-1925"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>FR</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Gore</surname><given-names>I</given-names></name><name><surname>Mooradian</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Croft</surname><given-names>EF</given-names></name><name><surname>DeVincenzo</surname><given-names>D</given-names></name><name><surname>Munley</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>D</given-names></name><name><surname>Freivogel</surname><given-names>K</given-names></name><etal/></person-group><article-title>Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA clinical access program (ICAP)</article-title><source>Cancer</source><volume>124</volume><fpage>2407</fpage><lpage>2414</lpage><year>2018</year><pub-id pub-id-type="doi">10.1002/cncr.31313</pub-id><pub-id pub-id-type="pmid">29579334</pub-id></element-citation></ref>
<ref id="b8-mmr-20-02-1925"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Jian</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ning</surname><given-names>G</given-names></name><name><surname>Bian</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name></person-group><article-title>Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling</article-title><source>Int J Oncol</source><volume>52</volume><fpage>1934</fpage><lpage>1946</lpage><year>2018</year><pub-id pub-id-type="pmid">29620167</pub-id><pub-id pub-id-type="pmcid">5919716</pub-id></element-citation></ref>
<ref id="b9-mmr-20-02-1925"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>Promoting roles of the secreted frizzled-related protein 2 as a Wnt agonist in lung cancer cells</article-title><source>Oncol Rep</source><volume>34</volume><fpage>2259</fpage><lpage>2266</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/or.2015.4221</pub-id><pub-id pub-id-type="pmid">26323494</pub-id><pub-id pub-id-type="pmcid">4583535</pub-id></element-citation></ref>
<ref id="b10-mmr-20-02-1925"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>R</given-names></name><name><surname>Motohashi</surname><given-names>S</given-names></name><name><surname>Sekine</surname><given-names>Y</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Iizasa</surname><given-names>T</given-names></name><name><surname>Hiroshima</surname><given-names>K</given-names></name><name><surname>Nakatani</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer</article-title><source>Clin Cancer Res</source><volume>13</volume><fpage>6087</fpage><lpage>6092</lpage><year>2007</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0591</pub-id><pub-id pub-id-type="pmid">17947472</pub-id></element-citation></ref>
<ref id="b11-mmr-20-02-1925"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Rong</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>L</given-names></name></person-group><article-title>Methylation-mediated loss of SFRP2 enhances invasiveness of non-small cell lung cancer cells</article-title><source>Hum Exp Toxicol</source><volume>37</volume><fpage>155</fpage><lpage>162</lpage><year>2018</year><pub-id pub-id-type="doi">10.1177/0960327117693071</pub-id><pub-id pub-id-type="pmid">29320940</pub-id></element-citation></ref>
<ref id="b12-mmr-20-02-1925"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>DC</given-names></name></person-group><article-title>Mitochondria and cancer</article-title><source>Nat Rev Cancer</source><volume>12</volume><fpage>685</fpage><lpage>698</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/nrc3365</pub-id><pub-id pub-id-type="pmid">23001348</pub-id><pub-id pub-id-type="pmcid">4371788</pub-id></element-citation></ref>
<ref id="b13-mmr-20-02-1925"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Siraj</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>FUNDC1-mediated mitophagy suppresses hepatocarcinogenesis by inhibition of inflammasome activation</article-title><source>Hepatology</source><volume>69</volume><fpage>604</fpage><lpage>621</lpage><year>2019</year><pub-id pub-id-type="doi">10.1002/hep.30191</pub-id><pub-id pub-id-type="pmid">30053328</pub-id></element-citation></ref>
<ref id="b14-mmr-20-02-1925"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>C</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Ming</surname><given-names>L</given-names></name></person-group><article-title>YAP Inhibits the apoptosis and migration of human rectal cancer cells via suppression of JNK-Drp1-Mitochondrial Fission-HtrA2/Omi pathways</article-title><source>Cell Physiol Biochem</source><volume>44</volume><fpage>2073</fpage><lpage>2089</lpage><year>2017</year><pub-id pub-id-type="doi">10.1159/000485946</pub-id><pub-id pub-id-type="pmid">29241219</pub-id></element-citation></ref>
<ref id="b15-mmr-20-02-1925"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Shui</surname><given-names>G</given-names></name><name><surname>Nie</surname><given-names>C</given-names></name></person-group><article-title>Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion</article-title><source>Cell Death Dis</source><volume>8</volume><fpage>e3151</fpage><year>2017</year><pub-id pub-id-type="doi">10.1038/cddis.2017.559</pub-id><pub-id pub-id-type="pmid">29072687</pub-id><pub-id pub-id-type="pmcid">5680924</pub-id></element-citation></ref>
<ref id="b16-mmr-20-02-1925"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>A</given-names></name><name><surname>Shimauchi</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Shimoda</surname><given-names>K</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Kitajima</surname><given-names>N</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Shindo</surname><given-names>N</given-names></name><name><surname>Numaga-Tomita</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hypoxia-induced interaction of filamin with Drp1 causes mitochondrial hyperfission-associated myocardial senescence</article-title><source>Sci Signal</source><volume>11</volume><issue>pii</issue><fpage>eaat5185</fpage><year>2018</year><pub-id pub-id-type="doi">10.1126/scisignal.aat5185</pub-id><pub-id pub-id-type="pmid">30425165</pub-id></element-citation></ref>
<ref id="b17-mmr-20-02-1925"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Jeong</surname><given-names>JI</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Kyung</surname><given-names>JW</given-names></name><name><surname>Baik</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>BY</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Inhibition of Drp1 ameliorates synaptic depression, abeta deposition, and cognitive impairment in an alzheimer&#x0027;s disease model</article-title><source>J Neurosci</source><volume>37</volume><fpage>5099</fpage><lpage>5110</lpage><year>2017</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2385-16.2017</pub-id><pub-id pub-id-type="pmid">28432138</pub-id><pub-id pub-id-type="pmcid">6596467</pub-id></element-citation></ref>
<ref id="b18-mmr-20-02-1925"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ni</surname><given-names>HM</given-names></name><name><surname>Xiong</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sesaki</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>WX</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Inhibition of Drp1 protects against senecionine-induced mitochondria-mediated apoptosis in primary hepatocytes and in mice</article-title><source>Redox Biol</source><volume>12</volume><fpage>264</fpage><lpage>273</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.redox.2017.02.020</pub-id><pub-id pub-id-type="pmid">28282614</pub-id><pub-id pub-id-type="pmcid">5344326</pub-id></element-citation></ref>
<ref id="b19-mmr-20-02-1925"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>The uremic toxin hippurate promotes endothelial dysfunction via the activation of Drp1-mediated mitochondrial fission</article-title><source>Redox Biol</source><volume>16</volume><fpage>303</fpage><lpage>313</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.redox.2018.03.010</pub-id><pub-id pub-id-type="pmid">29573704</pub-id><pub-id pub-id-type="pmcid">5953222</pub-id></element-citation></ref>
<ref id="b20-mmr-20-02-1925"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>Mst1 regulates non-small cell lung cancer A549 cell apoptosis by inducing mitochondrial damage via ROCK1/Factin pathways</article-title><source>Int J Oncol</source><volume>53</volume><fpage>2409</fpage><lpage>2422</lpage><year>2018</year><pub-id pub-id-type="pmid">30320378</pub-id><pub-id pub-id-type="pmcid">6203146</pub-id></element-citation></ref>
<ref id="b21-mmr-20-02-1925"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group><article-title>Wnt/beta-catenin signaling and disease</article-title><source>Cell</source><volume>149</volume><fpage>1192</fpage><lpage>1205</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id><pub-id pub-id-type="pmid">22682243</pub-id></element-citation></ref>
<ref id="b22-mmr-20-02-1925"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Gou</surname><given-names>WL</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>FAM3A attenuates ER stress-induced mitochondrial dysfunction and apoptosis via CHOP-Wnt pathway</article-title><source>Neurochem Int</source><volume>94</volume><fpage>82</fpage><lpage>89</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.neuint.2016.02.010</pub-id><pub-id pub-id-type="pmid">26939760</pub-id></element-citation></ref>
<ref id="b23-mmr-20-02-1925"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Salvador</surname><given-names>D</given-names></name><name><surname>Kulikauskas</surname><given-names>R</given-names></name><name><surname>Ruohola-Baker</surname><given-names>H</given-names></name><name><surname>Robitaille</surname><given-names>AM</given-names></name><name><surname>Chien</surname><given-names>AJ</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Sherwood</surname><given-names>V</given-names></name></person-group><article-title>WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner</article-title><source>Oncogene</source><volume>36</volume><fpage>3119</fpage><lpage>3136</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/onc.2016.450</pub-id><pub-id pub-id-type="pmid">28092677</pub-id><pub-id pub-id-type="pmcid">5467017</pub-id></element-citation></ref>
<ref id="b24-mmr-20-02-1925"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>E</given-names></name><name><surname>Rath</surname><given-names>E</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Waldschmitt</surname><given-names>N</given-names></name><name><surname>Khaloian</surname><given-names>S</given-names></name><name><surname>Allg&#x00E4;uer</surname><given-names>M</given-names></name><name><surname>Staszewski</surname><given-names>O</given-names></name><name><surname>Lobner</surname><given-names>EM</given-names></name><name><surname>Sch&#x00F6;ttl</surname><given-names>T</given-names></name><name><surname>Giesbertz</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mitochondrial function controls intestinal epithelial stemness and proliferation</article-title><source>Nat Commun</source><volume>7</volume><fpage>13171</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/ncomms13171</pub-id><pub-id pub-id-type="pmid">27786175</pub-id><pub-id pub-id-type="pmcid">5080445</pub-id></element-citation></ref>
<ref id="b25-mmr-20-02-1925"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DQ</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>XY</given-names></name><name><surname>Vaziri</surname><given-names>ND</given-names></name><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>YY</given-names></name></person-group><article-title>Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/beta-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease</article-title><source>Redox Biol</source><volume>12</volume><fpage>505</fpage><lpage>521</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.redox.2017.03.017</pub-id><pub-id pub-id-type="pmid">28343144</pub-id><pub-id pub-id-type="pmcid">5369369</pub-id></element-citation></ref>
<ref id="b26-mmr-20-02-1925"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>HQ</given-names></name></person-group><article-title>Specific knockdown of HOXB7 inhibits cutaneous squamous cell carcinoma cell migration and invasion while inducing apoptosis via Wnt/&#x03B2;-catenin signaling pathway</article-title><source>Am J Physiol Cell Physiol</source><volume>315</volume><fpage>C675</fpage><lpage>C686</lpage><year>2018</year><pub-id pub-id-type="doi">10.1152/ajpcell.00291.2017</pub-id></element-citation></ref>
<ref id="b27-mmr-20-02-1925"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b28-mmr-20-02-1925"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name></person-group><article-title>Aconitine induces apoptosis in H9c2 cardiac cells via mitochondriamediated pathway</article-title><source>Mol Med Rep</source><volume>17</volume><fpage>284</fpage><lpage>292</lpage><year>2018</year><pub-id pub-id-type="pmid">29115599</pub-id></element-citation></ref>
<ref id="b29-mmr-20-02-1925"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Toan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: A mechanism involving calcium overload/XO/ROS/mPTP pathway</article-title><source>Redox Biol</source><volume>16</volume><fpage>157</fpage><lpage>168</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.redox.2018.02.019</pub-id><pub-id pub-id-type="pmid">29502045</pub-id><pub-id pub-id-type="pmcid">5952878</pub-id></element-citation></ref>
<ref id="b30-mmr-20-02-1925"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>WG</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>XC</given-names></name></person-group><article-title>SPARCL1 suppresses cell migration and invasion in renal cell carcinoma</article-title><source>Mol Med Rep</source><volume>16</volume><fpage>7784</fpage><lpage>7790</lpage><year>2017</year><pub-id pub-id-type="doi">10.3892/mmr.2017.7535</pub-id><pub-id pub-id-type="pmid">28944877</pub-id></element-citation></ref>
<ref id="b31-mmr-20-02-1925"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Mff-Dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP Opening</article-title><source>J Am Heart Assoc</source><volume>6</volume><issue>pii</issue><fpage>e005328</fpage><year>2017</year><pub-id pub-id-type="pmid">28288978</pub-id><pub-id pub-id-type="pmcid">5524036</pub-id></element-citation></ref>
<ref id="b32-mmr-20-02-1925"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>PJ</given-names></name></person-group><article-title>Mitochondria, bioenergetics and apoptosis in cancer</article-title><source>Trends Cancer</source><volume>3</volume><fpage>857</fpage><lpage>870</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.trecan.2017.10.006</pub-id><pub-id pub-id-type="pmid">29198441</pub-id><pub-id pub-id-type="pmcid">5957506</pub-id></element-citation></ref>
<ref id="b33-mmr-20-02-1925"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Xin</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways</article-title><source>Redox Biol</source><volume>14</volume><fpage>576</fpage><lpage>587</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.redox.2017.11.004</pub-id><pub-id pub-id-type="pmid">29149759</pub-id></element-citation></ref>
<ref id="b34-mmr-20-02-1925"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>Mitochondrial dynamics and metastasis</article-title><source>Cell Mol Life Sci</source><volume>76</volume><fpage>827</fpage><lpage>835</lpage><year>2019</year><pub-id pub-id-type="doi">10.1007/s00018-018-2961-2</pub-id><pub-id pub-id-type="pmid">30415375</pub-id></element-citation></ref>
<ref id="b35-mmr-20-02-1925"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>36354</fpage><lpage>36367</lpage><year>2017</year><pub-id pub-id-type="pmid">28422739</pub-id><pub-id pub-id-type="pmcid">5482660</pub-id></element-citation></ref>
<ref id="b36-mmr-20-02-1925"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>ABT737 induces mitochondrial pathway apoptosis and mitophagy by regulating DRP1-dependent mitochondrial fission in human ovarian cancer cells</article-title><source>Biomed Pharmacother</source><volume>96</volume><fpage>22</fpage><lpage>29</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.111</pub-id><pub-id pub-id-type="pmid">28963947</pub-id></element-citation></ref>
<ref id="b37-mmr-20-02-1925"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paepe</surname><given-names>B</given-names></name><name><surname>Lefever</surname><given-names>S</given-names></name><name><surname>Mestdagh</surname><given-names>P</given-names></name></person-group><article-title>How long noncoding RNAs enforce their will on mitochondrial activity: Regulation of mitochondrial respiration, reactive oxygen species production, apoptosis, and metabolic reprogramming in cancer</article-title><source>Curr Genet</source><volume>64</volume><fpage>163</fpage><lpage>172</lpage><year>2018</year><pub-id pub-id-type="doi">10.1007/s00294-017-0744-1</pub-id><pub-id pub-id-type="pmid">28879612</pub-id></element-citation></ref>
<ref id="b38-mmr-20-02-1925"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>SE</given-names></name><name><surname>Sena</surname><given-names>LA</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name></person-group><article-title>Mitochondria in the regulation of innate and adaptive immunity</article-title><source>Immunity</source><volume>42</volume><fpage>406</fpage><lpage>417</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.002</pub-id><pub-id pub-id-type="pmid">25786173</pub-id><pub-id pub-id-type="pmcid">4365295</pub-id></element-citation></ref>
<ref id="b39-mmr-20-02-1925"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Qiang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway</article-title><source>Cell Death Dis</source><volume>9</volume><fpage>1143</fpage><year>2018</year><pub-id pub-id-type="doi">10.1038/s41419-018-1201-x</pub-id><pub-id pub-id-type="pmid">30446635</pub-id><pub-id pub-id-type="pmcid">6240078</pub-id></element-citation></ref>
<ref id="b40-mmr-20-02-1925"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsli-Uzunbas</surname><given-names>G</given-names></name><name><surname>Guo</surname><given-names>JY</given-names></name><name><surname>Price</surname><given-names>S</given-names></name><name><surname>Teng</surname><given-names>X</given-names></name><name><surname>Laddha</surname><given-names>SV</given-names></name><name><surname>Khor</surname><given-names>S</given-names></name><name><surname>Kalaany</surname><given-names>NY</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>CS</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>White</surname><given-names>E</given-names></name></person-group><article-title>Autophagy is required for glucose homeostasis and lung tumor maintenance</article-title><source>Cancer Discov</source><volume>4</volume><fpage>914</fpage><lpage>927</lpage><year>2014</year><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0363</pub-id><pub-id pub-id-type="pmid">24875857</pub-id><pub-id pub-id-type="pmcid">4125614</pub-id></element-citation></ref>
<ref id="b41-mmr-20-02-1925"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>W</given-names></name><name><surname>Matsuyama</surname><given-names>M</given-names></name><name><surname>Takemura</surname><given-names>H</given-names></name><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Shimono</surname><given-names>A</given-names></name></person-group><article-title>Sfrp1, Sfrp2, and Sfrp5 regulate the Wnt/beta-catenin and the planar cell polarity pathways during early trunk formation in mouse</article-title><source>Genesis</source><volume>46</volume><fpage>92</fpage><lpage>103</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/dvg.20369</pub-id><pub-id pub-id-type="pmid">18257070</pub-id></element-citation></ref>
<ref id="b42-mmr-20-02-1925"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>MT</given-names></name><name><surname>Lai</surname><given-names>HC</given-names></name><name><surname>Sytwu</surname><given-names>HK</given-names></name><name><surname>Yan</surname><given-names>MD</given-names></name><name><surname>Shih</surname><given-names>YL</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Yu</surname><given-names>MH</given-names></name><name><surname>Liu</surname><given-names>HS</given-names></name><name><surname>Chu</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name></person-group><article-title>SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway</article-title><source>Gynecol Oncol</source><volume>112</volume><fpage>646</fpage><lpage>653</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.ygyno.2008.10.026</pub-id><pub-id pub-id-type="pmid">19095296</pub-id></element-citation></ref>
<ref id="b43-mmr-20-02-1925"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Mohanbhai</surname><given-names>SJ</given-names></name><name><surname>Tiwari</surname><given-names>V</given-names></name><name><surname>Chaturvedi</surname><given-names>RK</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name></person-group><article-title>Axin-2 knockdown promote mitochondrial biogenesis and dopaminergic neurogenesis by regulating Wnt/beta-catenin signaling in rat model of Parkinson&#x0027;s disease</article-title><source>Free Radic Biol Med</source><volume>129</volume><fpage>73</fpage><lpage>87</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.08.033</pub-id><pub-id pub-id-type="pmid">30176346</pub-id></element-citation></ref>
<ref id="b44-mmr-20-02-1925"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TL</given-names></name><name><surname>Ouyang</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>LZ</given-names></name></person-group><article-title>&#x03B2;-Asarone suppresses Wnt/&#x03B2;-catenin signaling to reduce viability, inhibit migration/invasion/adhesion and induce mitochondria-related apoptosis in lung cancer cells</article-title><source>Biomed Pharmacother</source><volume>106</volume><fpage>821</fpage><lpage>830</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.009</pub-id><pub-id pub-id-type="pmid">29990876</pub-id></element-citation></ref>
<ref id="b45-mmr-20-02-1925"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunjiao</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Lyu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>K</given-names></name></person-group><article-title>High concentration of aspirin induces apoptosis in rat tendon stem cells via inhibition of the Wnt/&#x03B2;-catenin pathway</article-title><source>Cell Physiol Biochem</source><volume>50</volume><fpage>2046</fpage><lpage>2059</lpage><year>2018</year><pub-id pub-id-type="doi">10.1159/000495050</pub-id><pub-id pub-id-type="pmid">30415260</pub-id></element-citation></ref>
<ref id="b46-mmr-20-02-1925"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name></person-group><article-title>Nur77 promotes cerebral ischemia-reperfusion injury via activating INF2-mediated mitochondrial fragmentation</article-title><source>J Mol Histol</source><volume>49</volume><fpage>599</fpage><lpage>613</lpage><year>2018</year><pub-id pub-id-type="doi">10.1007/s10735-018-9798-8</pub-id><pub-id pub-id-type="pmid">30298449</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-20-02-1925" position="float">
<label>Figure 1.</label>
<caption><p>Effects of SFRP2 on A549 NSCLC cell apoptosis. (A and B) Protein and (C) mRNA expression of SFRP2 in the NSCLC cell line A549 and normal pulmonary epithelial cell line BEAS-2B. (D and E) Immunofluorescence was used to detect the expression of SFRP2. &#x002A;P&#x003C;0.05 vs. BEAS-2B. (F and G) Expression of SFRP2 following infection with ad-SFRP2 as determined via western blotting. (H) MTT assay measuring A549 cell viability following overexpression of SFRP2. (I and J) TUNEL staining was performed to determine the effects of SFRP2 on A549 cell apoptosis. &#x002A;P&#x003C;0.05 vs. Ctrl. SFRP2, secreted frizzled-related protein 2; NSCLC, non-small cell lung cancer; ad-SFRP2, SFRP2 overexpression adenoviral vector; ad-Ctrl, control adenovirus; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.</p></caption>
<graphic xlink:href="MMR-20-02-1925-g00.jpg"/>
</fig>
<fig id="f2-mmr-20-02-1925" position="float">
<label>Figure 2.</label>
<caption><p>SFRP2 overexpression is associated with mitochondrial damage. (A) Overexpression of SFRP2 decreased ATP generation. (B and C) Mitochondrial potential was evaluated via JC-1 staining. Red fluorescence indicated a normal mitochondrial potential, whereas green fluorescence indicated depolarization of the mitochondrial potential. (D) Effects of SFRP2 overexpression on mPTP opening. (E-G) Mitochondrial respiratory complex protein activity was measured. SFRP2 overexpression inhibited the activity of the mitochondrial respiratory complex. (H-K) Western blotting was used to analyze the protein expression levels of caspase3, Bax and c-IAP. &#x002A;P&#x003C;0.05 vs. Ctrl. SFRP2, secreted frizzled-related protein 2; ad-SFRP2, SFRP2 overexpression adenoviral vector; ad-Ctrl, control adenovirus; mPTP, mitochondrial permeability transition pore; ETCx, electron transport chain complex; c-IAP, cellular inhibitor of apoptosis protein.</p></caption>
<graphic xlink:href="MMR-20-02-1925-g01.jpg"/>
</fig>
<fig id="f3-mmr-20-02-1925" position="float">
<label>Figure 3.</label>
<caption><p>SFRP2 is associated with mitochondrial damage by activating mitochondrial fission. (A) Mitochondrial import receptor subunit TOM20 homolog was used to observe mitochondrial fission or mitochondrial debris. (B) Quantification of mitochondrial fission via mitochondrial length. Effects of mitochondrial fission on (C) ATP generation, (D) mPTP opening and (E) apoptosis in A549 cells. &#x002A;P&#x003C;0.05 vs. Ctrl; <sup>#</sup>P&#x003C;0.05 vs. ad-SFRP2. SFRP2, secreted frizzled-related protein 2; ad-SFRP2, SFRP2 overexpression adenoviral vector; ad-Ctrl, control adenovirus; Mdivi1, mitochondrial division inhibitor 1; mPTP, mitochondrial permeability transition pore; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.</p></caption>
<graphic xlink:href="MMR-20-02-1925-g02.jpg"/>
</fig>
<fig id="f4-mmr-20-02-1925" position="float">
<label>Figure 4.</label>
<caption><p>Effects of mitochondrial fission on A549 cell proliferation and metastasis. (A and B) EdU assay determining cellular proliferation. The number of EdU-positive cells was measured. (C-E) Transwell assays determining the migratory and invasive abilities of A549 cells following SFRP2 overexpression and fission inhibition (scale bars, 100 &#x00B5;m). &#x002A;P&#x003C;0.05 vs. Ctrl; <sup>#</sup>P&#x003C;0.05 vs. ad-SFRP2. SFRP2, secreted frizzled-related protein 2; ad-SFRP2, SFRP2 overexpression adenoviral vector; ad-Ctrl, control adenovirus; Mdivi1, mitochondrial division inhibitor 1; EdU, 5-ethynyl-2&#x2032;-deoxyuridine.</p></caption>
<graphic xlink:href="MMR-20-02-1925-g03.jpg"/>
</fig>
<fig id="f5-mmr-20-02-1925" position="float">
<label>Figure 5.</label>
<caption><p>Role of the Wnt signaling pathway in SFRP2-mediated fission. (A) Protein levels of (B) &#x03B2;-catenin, (C) c-myc and (D) Drp1 were evaluated via western blotting. IWR-1 was used in A549 cells to inhibit the Wnt signaling pathway &#x002A;P&#x003C;0.05 vs. Ctrl. SFRP2, secreted frizzled-related protein 2; ad-SFRP2, SFRP2 overexpression adenoviral vector; ad-Ctrl, control adenovirus; IWR-1, inhibitor of Wnt response 1; Drp1, Dynamin-related protein 1</p></caption>
<graphic xlink:href="MMR-20-02-1925-g04.jpg"/>
</fig>
</floats-group>
</article>